Every Cure

Every Cure to Receive $48.3M from Advanced Research Projects Agency for Health (ARPA-H) to Develop AI-Driven Platform to Revolutionize Future of Drug Development and Repurposing ARPA-H contract will supercharge Every Cure’s work to identify existing medicines that can be repurposed to treat currently untreated diseases. Initial progress utilizing a pilot version of the AI platform and stakeholder engagement has led to the identification of potential treatments for sickle cell disease, ALS, and autism spectrum disorder. https://lnkd.in/d6wVWutU

Every Cure’s algorithms create detailed profiles for every drug and disease, then assign a score to determine how well they match. By leveraging generative AI, we’re able to rapidly sift through countless studies in seconds—something that would take humans days. This technology is helping us identify life-saving treatments far more efficiently. It’s been the honor of my lifetime to work at the University of Pennsylvania and through Every Cure to help save lives with cures that are sitting on pharmacy shelves, waiting to be discovered. #AIInHealthcare #DrugRepurposing #HealthcareInnovation #EveryCure #MedicalResearch #PatientCare

A huge thank you to STAT and Matthew Herper for running this exclusive on our recent announcement! Click the link below to read the full article! https://lnkd.in/epjKpjHb

Every Cure Announces Janet Woodcock, Former Acting Commissioner of the FDA has joined its Board of Directors! Dr. Woodcock's decades of experience in drug evaluation and research, along with her long-standing career at the FDA, will bring invaluable insights and expertise to our team. Read the full story here: https://lnkd.in/epjKpjHb Janet Woodcock recently completed a long career at the FDA.?She served as Director of the Center for Drug Evaluation and Research for over twenty years in several stretches. Most recently she served as Principal Deputy Commissioner and prior to that as Acting FDA Commissioner.?She held multiple other senior positions at FDA including at the Center for Biologics Evaluation and Research. She was the therapeutics lead for “Operation Warp Speed” during the COVID pandemic. Her most recent effort was spearheading a major reorganization of FDA’s foods program and the Office of Regulatory Affairs. Dr. Woodcock completed many major regulatory initiatives during her FDA tenure.?She was instrumental in getting the biosimilars legislation enacted and worked to ensure adoption in the clinical community. Additionally, she worked with industry and Congress to bring about the first GDUFA.?After passage of the legislation, she oversaw an extensive reorganization of the generic drug review program at CDER, that successfully met the aggressive targets of the legislation and led to eventual reauthorizing, with elimination of backlogs and approval of thousands of generic drugs.

At 25 years old, my doctors didn’t think I was going to survive. They had run out of options for treating my rare and deadly disease. A priest even read me my last rites as my family said their final goodbyes. I somehow survived, thanks to a regimen of seven different chemotherapies, but I knew I would relapse again if I didn’t treat the underlying cause of my disease. I started running experiments on my cells and found that a communication line called mTOR was turned into overdrive. The best part was that there was already a drug made for a different disease that inhibited mTOR. I began taking that drug and have now been in remission for over 10 years! It begs the question: What other diseases could we find cures for if we maximized the uses of existing drugs? That’s why I co-founded @EveryCure, a non-profit that utilizes artificial intelligence to unlock the full potential of existing drugs! Go to EveryCure.org to join us on this mission! #medicine #raredisease #doctor

Today we are excited to feature the Chair of our Scientific Advisory Board, Ruxandra Draghia Akli, MD, PhD! Dr. Draghia-Akli serves as the Chair of the Scientific Advisory Board at Every Cure. Her extensive career in human genetics, rare diseases, gene therapies, and nucleic acid vaccines has made substantial contributions to public health. At Johnson & Johnson, she spearheaded the establishment of a Global Public Health R&D organization focused on developing solutions for critical health threats like Dengue and tuberculosis. She has played pivotal roles in the European Commission’s health initiatives and co-chaired the ACTIV program, initiated by the U.S. National Institutes of Health. Dr. Draghia-Akli will join Novavax in November 2024 as Executive Vice President and Head of Research & Development (R&D). As Chair of the Scientific Advisory Board for Every Cure, Dr. Draghia-Akli will utilize her vast experience and strategic vision to guide Every Cure’s efforts in identifying and advancing drug repurposing opportunities with the greatest potential impact.

The Castleman Disease Collaborative Network and my Center at Penn are currently searching for several key positions! We're looking for people who are passionate about making an impact and contributing to groundbreaking research in rare diseases to join our team in the following roles: - CDCN Scientific Director (PhD, to work with physicians and researchers around the world to develop and advance a collaborative research strategy):?https://lnkd.in/esaswVRH - Coming Soon: Director of Strategy & Admin (or "Chief of Staff") in the Center for Cytokine Storm Treatment & Laboratory at Penn - to partner with me as my right-hand person. MS, MBA, or PhD. If you’re interested, email me at?[email protected] - Biomedical Leadership Fellow (MD student taking a year out to lead and contribute to a wide range of biomedical projects and initiatives):?https://lnkd.in/et5y22ir - CDCN Program Coordinator:?https://lnkd.in/eagqw9fp Know someone who might be a good fit? Please share this post or tag them below! More info here:?https://lnkd.in/ehwdxbSx #Hiring #JobOpportunity #CDCN #CastlemanDisease #HealthcareJobs #JoinOurTeam #RareDiseases

I had a great time on the People’s Pharmacy Podcast where we spoke about unlocking the lifesaving potential of old drugs! Click the link below to listen to the full episode: https://lnkd.in/eQKKJgGW

I had a great time keynoting on behalf of Every Cure at Biochem Alchemy in Philadelphia last week. Thank you to the Emily Whitehead Foundation and all the other organizers of this incredible event! Please find my full talk below:

A thought-provoking discussion on envisioning a future without Pharma with Craig Lipset, Tracey Sikora, Craig Martin, and Len Rosenberg. They are challenging preconceived notions to shape a future in drug development beyond traditional pharmaceutical-driven trials and research. #Innovators #DrugDevelopment #FutureOfMedicine #innovation #innovateinwhatyoudo